The revenue growth comes amid increased demand for the company's molecular genetics products.
Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.
The kit detects the three most common aneuploidies associated with bladder cancer, as well as deletions of the 9p21.3 locus.
Sengenics is rebranding the technology Immunome and expects it to expand the company's footprint in the proteomics space.
The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.
The company plans to launch a suite of small cancer panels initially for research, but it could eventually seek regulatory approval for them as diagnostics.
The arrays feature the addition of newly identified genomic regions, as well as the removal of ones found to have no pathogenic significance.
While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.
RHS recently acquired an Arrayjet Marathon instrument to produce EmbryoCellect, which competes with PGS kits sold by Illumina, Agilent Technologies, OGT, and others.
For the first time ever, the privately held, Oxford, UK-based company reported its total and commercial revenues.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.